Guggenheim initiates First Tracks Biotherapeutics Buy, $100 target
Guggenheim initiated coverage on First Tracks’s stock with a Buy rating and a $100.00 price target, implying 159.9% upside from the Sep 15 close of $38.47.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.